Wesana Health is a data-driven life science company focused on the delivery and development of therapies, including psychedelics, to treat traumatic brain injury (TBI), migraines, depression and anxiety.
Wesana Health
The company is creating evidence-based formulations and developing protocols that target neurological, psychological and mental health ailments due to head trauma. The lead program aims to combine psilocybin and cannabidiol (CBD). Wesana has also donated $1.5 million to MAPS PBC to study MDMA for TBI.
Wesana was founded by two-time Stanley Cup winner Daniel Carcillo after his own personal experiences with brain injury and concussion as a result of his playing career.
Wesana Health’s primary goal is to transform the landscape for the treatment of neurological health and performance through the use of personalized medicine, including novel formulations, psychedelics and technology.
Activities
B2C
Biotech
Drug Discovery
Compounds of Interest
MDMA
Psilocybin
Explore more company info with a Tree membership
📰 Weekly newsletter about the business of psychedelics
📈 Extended company information (analyst view, fundraising, revenue numbers)
🪄 Priority company page updates
Company News
Wesana Health Announces New Findings Indicating Psilocybin Potentiates Impact of an Anti-Depressant (GlobeNewswire, 22 March 2022)Wesana Announces Singular Focus on Drug Development Prompting a Strategic Review of its Clinics and Other Care Delivery Assets (Market Watch, 05 May 2022)
Wesana Health Announces Positive Feedback From Pre-IND Meeting With FDA on SANA-013 (Wesana Health, 14 March 2022)
Wesana Is Exploring Broadening SANA-013 Lead Indication to Treat Major Depressive Disorder (Financial Post, 19 April 2022)
Wesana Health Clinics Surpass 4,000 Administered Ketamine Treatments (Press Release, 19 November 2021)
Wesana announced today that the company’s Wesana Clinics business segment has surpassed 4,000 administered ketamine treatments for major depressive disorder, anxiety, PTSD, and addiction since inception.